Marshall Wace LLP Trims Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Marshall Wace LLP trimmed its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 94.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,835 shares of the company's stock after selling 110,846 shares during the quarter. Marshall Wace LLP's holdings in Kymera Therapeutics were worth $275,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KYMR. Blue Trust Inc. increased its position in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares in the last quarter. KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the last quarter. PEAK6 LLC acquired a new stake in Kymera Therapeutics during the fourth quarter worth about $302,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $310,000.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent analyst reports. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target for the company. Stephens restated an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, HC Wainwright lifted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Trading Up 1.9 %

KYMR traded up $0.54 on Wednesday, hitting $29.11. 730,110 shares of the company were exchanged, compared to its average volume of 562,781. The firm has a 50-day moving average price of $29.57 and a two-hundred day moving average price of $37.91. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -12.44 and a beta of 2.18. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.